Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Apogee Therapeutics, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have a diagnosis of AD that has been present for \>=1 year prior to the Screening visit
Moderate-to-severe AD at Screening and Baseline visits
History of inadequate response to treatment with topical medications, or medical determination that topical therapies are inadvisable
Applied a stable dose of non-medicated over-the-counter emollient/moisturizer of their choice on their skin for \>=14 days prior to Baseline visit and agrees to continue using the same moisturizer throughout the study except the day of the study visits.
Have completed itch questionnaires in the electronic diary for \>=4 of 7 days prior to Baseline visit
You may not be if
Participation in a prior study with APG777.
Prior treatment with protocol-specified monoclonal antibodies (mAbs)
Has used any AD-related topical medications within 7 days prior to Baseline visit.
Has used systemic treatments (other than biologics) and/or phototherapies and/or laser therapy that could affect AD within 4 weeks prior to Baseline visit
Clareo Health | A Study Evaluating APG777 in Atopic Dermatitis
